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Background: An advanced bipolar (ABP) tissue sealer designed for division of major vessels in open
procedures was evaluated in a prospective post-market study. The objective was to provide clinical data
for assessment of vessel transection, hemostatic performance and ease of use of the ABP device during
open colectomy, gynecologic, and thoracic operations.
Materials and methods: The ABP test device was used in colectomy (n ¼ 36), gynecologic (n ¼ 44), and
thoracic (n ¼ 21) procedure groups. Vessels transected with the ABP device were graded intraoperatively
on a hemostasis scale of 1e4, defined as follows: Grade1, no bleeding; Grade 2, minor bleeding with no
intervention; Grade 3, minor bleeding requiring touchup with the test device or monopolar cautery; and
Grade 4, significant bleeding requiring intervention with any additional hemostatic product. The primary
performance measure was the percentage of vessels that achieved hemostasis grades 3. The primary
safety endpoint was the summarization of all ABP device-related adverse events (AEs).
Results: For all three procedure groups together, 302 (96.2%) of 314 total vessel transections were scored
as hemostasis grades  3, including 270 (86.0%) that were rated Grade 1. Twelve transections (3.8%) were
Grade 4, which included 9 vessels transected in the gynecologic group and 3 in the thoracic group. Three
subjects experienced a total of 4 device-related AEs, consisting of hematoma, hypotension, procedural
pain, and superficial thermal burn. All 4 device-related AEs were mild in severity.
Conclusion: The advanced bipolar device exhibited effective hemostasis, an acceptable safety profile, and
ease of use during colectomy, thoracic, and gynecologic procedures.
Trial registry number: ClinicalTrials.gov, NCT034411.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bipolar electrosurgical devices are widely used in a variety of
surgical specialties for sealing and transection of blood vessels as
well as dissection of tissues. In clinical use, advanced bipolar tech-
nology may have advantages relative to other surgical approaches.
For example, current flow is largely confined to tissue held between
the instrument's jaws, which promotes effective vessel sealing andon).
vier Ltd on behalf of Surgical Asso
User (n/a) at The University of Edinb
. No other uses without permission. Creduced risk of thermal injury. Investigators have found that in
abdominal or laparoscopic hysterectomy procedures, bipolar sealers
were associated with reduced operative time, lower blood loss, less
postoperative pain, and similar or better clinical outcomes versus
conventional suture ligation of blood vessels [1e7]. A comparative
study of laparoscopic colorectal resections using bipolar sealing
versus clips and staplers found the mean time needed for vascular
pedicle control was significantly reducedwith the bipolar device [8].
In another study of colorectal surgery, intraoperative bleeding from
the inferior mesenteric artery (IMA) was observed in 6 of 400 (1.5%)ciates Ltd. This is an open access article under the CC BY-NC-ND license (http://
urgh from ClinicalKey.com by Elsevier on May 04, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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device [9]. The authors concluded that the bipolar device could be
safely employed for vascular control of the IMA. For patients un-
dergoing Ivor-Lewis esophagectomy, advanced bipolar sealers were
associated with lower intraoperative bleeding and faster operative
times compared to conventional hemostatic clamp and tie methods
[10,11]. Taken together, these studies suggest effective use of bipolar
technology with regard to hemostatic control.
The advanced bipolar (ABP) device evaluated in this study was
specifically designed for open procedures involving division of
major vessels. The device is used for tissue dissection, grasping, and
transection of vasculature in general, gynecologic, thoracic and
vascular surgeries and may be used to seal and transect vessels
(arteries, veins, pulmonary vasculature, lymphatics) up to and
including 7 mm in diameter. Features include 360 shaft rotation
for easier access to targeted tissue, enhanced ergonomics, and in-
dependent sealing and cutting functions. In initial bench-top and
preclinical studies, the ABP device exhibited similar sealing
strength of porcine vessels compared to another advanced bipolar
instrument [12]. Hemostasis at the distal tip was significantly
better for the ABP versus the comparator device, when each was
applied to thick mesentery tissue. The purpose of the current study
was to evaluate vessel transection, hemostatic performance and
ease of use of the ABP device in a post-market clinical setting, in
three open procedure groups: colectomy, gynecologic, and thoracic.
2. Methods
2.1. Study design
This study was a prospective, multicenter, single-arm, cohort
analysis of procedures performed with an ABP device (ENSEAL® X1
Large Jaw Tissue Sealer, Ethicon Endo-Surgery, Inc., Cincinnati OH,
USA), at 6 total institutions in the United Kingdom and USA. The
studywas carried out to provide postmarket clinical follow-up data
on performance and safety of the device. The protocol and consent
form were approved by each investigator's Institutional Review
Board or Independent Ethics Committee. The study was registered
with ClinicalTrials.gov (registry number NCT03441178) and con-
ducted in accordance with Good Clinical Practice and the Declara-
tion of Helsinki, as well as any other applicable local, state and
federal requirements. Participating surgeons carried out the oper-
ations in accordance with their own standard surgical approach,
using the ABP per its instructions for use. Each surgeon/investigator
underwent training with the ABP test device prior to the study.
During the study, more than one surgeonmay have participated per
case, but only one investigator utilized the test device in any given
surgery. The protocol included a minimum of 3 visits: screening
within 8 weeks prior to surgery, performance of the procedure
through discharge, and a postoperative visit or phone call
approximately 4 weeks after the procedure.
2.2. Subject Selection and procedure groups
In order to generate a representative patient sample, consecu-
tive subjects scheduled to undergo an elective surgery from the
proposed procedure groups were considered for participation in
the study. Informedwritten consent was obtained for all subjects. A
total of 100 subjects were planned to be enrolled, including a
minimum of 30 colectomy procedures, 30 gynecologic procedures,
and 20 thoracic procedures. The remaining 20 subjects were
enrolled into any of the three procedural groups. Subjects were
consented and screened anytime between scheduling of the oper-
ation and hospital admission. They were considered enrolled at the
time of the first attempted vessel transection with the ABP device.Downloaded for Anonymous User (n/a) at The University of Ed
For personal use only. No other uses without permissioInclusion criteria were: at least one planned vessel to be transected
with the ABP; willingness to consent and comply with study-
related evaluations and treatment schedule; minimum age of 18
years. Criteria for exclusion were concurrent enrollment in a
different clinical study, or any condition (physical or psychological)
that would impair study participation. Elective open colectomy,
gynecologic, or thoracic procedures were performed per each
institution's standard of care approach, where the ABP device was
utilized for vessel sealing and transection.
2.3. Performance and safety endpoints
The primary performance endpoint was the percentage of blood
vessels transected using the ABP device in which hemostasis was
achieved without the need for additional hemostatic products (e.g.
hemoclips, staples, sutures, fibrin sealants, other advanced energy).
Either no bleeding at the transection site, or minor bleeding that
may require touch-up with the ABP device or a monopolar device
were considered successful hemostasis and counted in this per-
centage. The primary endpoint was determined separately for each
procedure group and for the entire subject set and was based on an
assessment of hemostasis for all vessels transected with the test
device. Each vessel transection was counted and graded for hemo-
stasis intraoperatively. The hemostasis scalewas defined as: Grade 1,
no bleeding at the transection site; Grade 2, minor bleeding at the
transection site that does not require intervention; Grade 3, minor
bleeding at the transection site requiring touch-upwith the ABP test
device or monopolar cautery; Grade 4, significant bleeding (e.g.,
pulsatile blood flow, venous pooling) requiring intervention such as
extensive coagulation or ligation with additional hemostatic prod-
ucts including hemoclips, staples, sutures, fibrin sealants, or another
advanced energy device. Secondary endpoint measures were the
distribution of vessel hemostasis grades in each procedure group,
the incidence of ABP touch-ups for Grade 3, and incidence of specific
types of Grade 4 interventions required to obtain hemostasis. The
primary safety endpoint was the summarization of all test device-
related adverse events (AEs), which were assessed for seriousness,
severity, action taken, and outcome. In addition, investigators were
asked to complete questionnaires to assess their experience with
the study device. These included a short device questionnaire after
each surgery, and a longer questionnaire following each inves-
tigator's second procedure in the study.
2.4. Statistical methods
The study planned to enroll a sample size of at least 100 patients,
which was considered sufficient for a descriptive summary of per-
formance endpointswithin each procedural group. Thiswas a single-
arm study (no comparator device), and thus the sample size was not
statistically sized. Estimation of endpoints was performed using 95%
confidence intervals. At least 2 vessels were expected to be trans-
ected with the ABP test device per procedure, providing a minimum
of 60 transections in each of the colorectal and gynecologic groups,
and 40 within the thoracic procedures. The analysis sets used for
summarization of performance and safety endpoints included all
patients in whom the test device was utilized during the procedure.
Performance and safety endpoints were summarized separately for
each procedure group, as well as for the entire pooled subject set.
3. Results
3.1. Subject selection and demographic data
A total of 108 subjects were screened for enrollment, and 101
underwent surgery in one of the three procedure groups includinginburgh from ClinicalKey.com by Elsevier on May 04, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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The study covered the period from March 13, 2018 (date of first
enrollment) through August 30, 2019 (last postoperative visit). All
subjects in whom the ABP device was used for transection of at
least one blood vessel were included for analysis. Ninety-nine
(98.0%) subjects completed the study through the final post-
operative visit. One from the gynecologic group died during the
study due to an acute ischemic bowel event that was considered
unrelated to the test device. One thoracic subject underwent a
gastric procedure that was not defined in the protocol. Table 1 lists
demographic data for the subject population. Mean age was 61.8
years (range 28.0e89.0), with thoracic subjects' average age being
older than the other two groups. A majority in each procedure
group (95.0% overall) wereWhite and 57.5% of overall subjects were
current or former smokers. Body mass index was similar between
groups.
3.2. Specific procedures and indications
Table 2 summarizes the types of operations performed within
each group. The open colectomy group included multiple left-sided
procedures (e.g. low anterior resection, sigmoid colectomy, and
Hartmann's operation) which accounted for 47.2% of the surgeries.
Right-sided colectomies were performed in 9 (25.0%) cases. In the
gynecologic subjects, total abdominal hysterectomywas performed
in 25 (56.8%) surgeries in combination with salpingo-
oophorectomy or salpingectomy. The thoracic procedures con-
sisted predominantly of transthoracic esophagectomies in 15
(71.4%), which included Ivor-Lewis (n ¼ 14) and three-field (n ¼ 1)
techniques. The most common disease indication in the colectomy
group was colorectal cancer, which was present in 22 of 36 cases
(61.6%), followed by inflammatory bowel disease (Crohn's or Ul-
cerative colitis) in 6 (16.7%), and colon polyps or other conditions inScreenin
eligibi
(N = 1










Fig. 1. Subject Selection and Procedure Groups. All 101 subjects who underwent surgery w
51 subjects, and 50 were enrolled in the USA.
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included ovarian cancer in 18 of 44 (40.9%) procedures, ovarian cyst
in 6 (13.6%), prolapse in 6 (13.6%), uterine cancer in 4 (9.1%), and
abnormal bleeding, fibroids, or other conditions in 10 (22.7%)
procedures. In the thoracic group, esophageal cancer was the pri-
mary indication in 15 of 21 (71.4%) subjects, followed by benign
esophageal disease or other conditions in 6 (28.6%) cases.
3.3. Hemostasis grading and operative data
The total number of arteries and veins transected and hemo-
stasis grading for each procedure group are summarized in Table 3.
Of 314 total vessels transected, 302 (96.2%) achieved Grade 3 or
lower (better) hemostasis scores, with 11 (3.5%) vessels requiring at
least one hemostatic touchup (Grade 3 hemostasis). Compression
was used three times, while monopolar energy or the ABP device
were used in six and eight instances, respectively for touchups.
Analyses of each procedure group showed that Grade 3 or lower
hemostasis scores were achieved for 94.2%, 96.7%, and 100.0% of
transections in gynecologic, thoracic, and colectomy procedures,
respectively. Across all procedures, 86.0% of transections were rated
as Grade 1 (i.e. no bleeding at the transection site). The mean
(median) intraoperative blood loss for each procedure group was
437 (300) ml. Table 4 summarizes the Grade 4 transections re-
ported for the entire subject set. Across all procedures there were
12 (3.8%) Grade 4 hemostasis ratings. No Grade 4 ratings were
observed in the colectomy group. In gynecologic procedures there
were 9 (5.8%) Grade 4 vessel transections, including eight occur-
rences in uterine arteries. For all uterine artery transections
(left þ right), Grade 4 hemostasis was observed in 8 of 68 (11.8%)
vessels. Other Grade 4 hemostasis events occurred in 1 of 66 (1.5%)
ovarian arteries, and 3 vessels in thoracic procedures: 2 of 70 (2.9%)
short gastric and 1 of 15 (6.7%) gastroepiploic. Sutures were usedg for 
lity
08)
 UK (n = 51)
s (N = 101)
Thoracic
(n = 21)
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Age at Consent (years)
Mean (SD) 60.9 (13.4) 59.9 (13.3) 67.6 (6.2) 61.8 (12.5)
Median (Min, Max) 61.5 (32.0, 89.0) 61.0 (28.0, 88.0) 67.0 (57.0, 85.0) 63.0 (28.0, 89.0)
Gender
Male 19 (52.8%) 0 (0.0%) 14 (66.7%) 33 (32.7%)
Female 17 (47.2%) 44 (100.0%) 7 (33.3%) 68 (67.3%)
Race
White 35 (97.2%) 40 (90.9%) 21 (100.0%) 96 (95.0%)
Black/African American 1 (2.8%) 1 (2.3%) 0 (0.0%) 2 (2.0%)
Native Hawaiian 0 (0.0%) 1 (2.3%) 0 (0.0%) 1 (1.0%)
Asian 0 (0.0%) 1 (2.3%) 0 (0.0%) 1 (1.0%)
Not reported 0 (0.0%) 1 (2.3%) 0 (0.0%) 1 (1.0%)
Body Mass Index (kg/m2)
Mean (SD) 27.6 (7.8) 28.1 (6.7) 27.5 (5.9) 27.8 (6.9)
Median (Min, Max) 25.8 (16.7, 52.5) 27.2 (17.7, 44.9) 26.8 (19.2, 43.4) 26.2 (16.7, 52.5)
Diabetes 4 (11.2%) 5 (11.4%) 1 (4.8%) 10 (9.9%)
Obesity 2 (5.6%) 1 (2.3%) 1 (4.8%) 4 (4.0%)
Hypertension 16 (44.4%) 16 (36.4%) 7 (33.3%) 39 (38.6%)
Current Smoker 5 (13.9%) 6 (13.6%) 2 (9.5%) 13 (12.9%)
Former smoker 15 (41.7%) 17 (38.6%) 13 (61.9%) 45 (44.6%)
(SD) standard deviation; (Min, Max) range minimum and maximum.
Table 2
Specific procedures performed.
Procedure Group Specific procedure n (%)
Colectomy N ¼ 36 Right colectomy (or ileocolectomy) 9 (25.0%)
Low anterior resection 7 (19.4%)
Sigmoid colectomy 7 (19.4%)
Hartmann procedure 2 (5.6%)
Left colectomy 1 (2.8%)
Sub-total colectomy 1 (2.8%)
Other 9 (25.0%)






TAH/subtotal with bilateral salpingectomy 3 (6.8%)
Bilateral salpingo-oophorectomy 3 (6.8%)
Other 16 (36.4%)
Thoracic N ¼ 21 Transthoracic esophagectomy 15 (71.4%)
Other 6 (28.6%)
(TAH) total abdominal hysterectomy.
J. Schilder et al. / International Journal of Surgery Open 24 (2020) 57e6360for additional hemostasis in all Grade 4 transections except for one
instance of hemoclip placement.
For all transections, 300 (95.5%) were reported as having no
sticking tissue. All 14 cases where sticking was identified were
rated as “slight sticking requiring activation of the ABP device to
release tissue”, with no cases requiring counter-tension or counter-
tension and extensive force. Although investigators could use their
method of choice for tissue dissection and isolation of vessels, 78
(77.2%) procedures overall utilized the ABP test device for this
purpose. Use of the test device for tissue dissection was done in
(95.5%) of gynecologic procedures, (77.8%) of colectomy cases, and
(38.1%) of thoracic procedures.3.4. Adverse events
This study collected all adverse events (AEs) that were deter-
mined to be specifically related to either the study procedure
(n ¼ 122) or the test device (n ¼ 4). A total of 43 (42.6%) subjects
reported at least one AE meeting these criteria: 15 (41.7%) colec-
tomy subjects; 20 (45.5%) gynecologic subjects; and 8 (38.1%)
thoracic subjects. The 4 device-related AEs included hematoma andDownloaded for Anonymous User (n/a) at The University of Ed
For personal use only. No other uses without permissiohypotension in 1 (2.8%) colectomy subject, procedural pain in 1
(2.3%) gynecologic subject, and a superficial thermal burn in 1
(2.3%) gynecologic subject. The burn was approximately 0.5 cm in
length in the vulvar area and required no intervention. It was
thought to have been caused by the test device, whereas the
remaining 3 events were considered to have an unlikely relation-
ship to the device. Twelve (11.9%) subjects experienced at least one
serious adverse event (SAE) during the study. None of the 15 total
SAEs were related to the study device. All AEs were also classified
for clinical relevance per the Clavien-Dindo (CD) surgical compli-
cations scale (Table 5) [13]. Of 122 procedure-related AEs, 107
(87.7%) were scored as either CD Grades I or II. Higher CD grades
(Grade III) were assigned for 15 (12.3%) events, all from the
colectomy and thoracic groups. Therewere 3 (2.5%) AEs classified as
Grade IVa, consisting of two cases of respiratory failure and one
kidney injury. Importantly, all 4 device-related AEs were rated as
mild in severity and were classified as Clavien-Dindo Grade I
complications.
3.5. Questionnaires
The device questionnaires indicated that only one hand was
required to operate the ABP test device in 98 (97%) total procedures
across all three groups. In addition, the need to reposition the de-
vice or change hand position to activate the it was not required in
86.1% and 94.1% of procedures, respectively. Finally, the ABP study
device was considered easier to fire by 73.3% of (11 of 15) partici-
pating surgeons, compared to previously used advanced bipolar
instruments.
4. Discussion
This study included three procedure groups and 314 total vessel
transections performed with the ABP test device. With respect to
the primary endpoint measure, all 68 vessel transections in the
colectomy group were Grade 3 hemostasis or lower, and first pass
hemostasis was achieved (Grades 1 and 2 combined) with no
intervention required in 67 (98.5%) transections. Themost common
vessel transected in the colectomy group was the IMA (n ¼ 15), and
there were no cases of observed bleeding for this major artery.
Similarly, for right-sided colon resections, the primary ligatedinburgh from ClinicalKey.com by Elsevier on May 04, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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Total Number of Vessels Transected 68 156 90 314
Hemostasis Grading Scale
Grade 1 63 (92.6%) 126 (80.8%) 81 (90.0%) 270 (86.0%)
Grade 2 4 (5.9%) 14 (9.0%) 3 (3.3%) 21 (6.7%)
Grade 3 1 (1.5%) 7 (4.5%) 3 (3.3%) 11 (3.5%)
Grade 4 0 (0.0%) 9 (5.8%) 3 (3.3%) 12 (3.8%)
Vessels Scored Grade 3 or lower 68 (100.0%) 147 (94.2%) 87 (96.7%) 302 (96.2%)
Exact 95% Confidence Interval 94.7%,100.0% 89.3%,97.3% 90.6%,99.3% 93.4%,98.0%
Grade 3 Compressions 0 3 0 3
Grade 3 Touchups
Number Using Monopolar 1 3 2 6
Number Using ENSEAL X1 0 7 1 8
Procedure Duration (hrs)
Mean (SD) 4.1 (2.2) 2.4 (1.1) 4.5 (1.7) 3.4 (1.9)
Median (Min, Max) 3.7 (1.6, 10.5) 2.4 (0.8, 4.6) 5.0 (1.4, 7.0) 3.0 (0.8, 10.5)
Intraoperative Blood Loss (ml)
Mean (SD) 407.5 (771.0) 436.4 (420.0) 275.3 (231.7) 393.8 (548.4)
Median (Min, Max) 200.0 (20.0, 4500.0) 300.0 (85.0, 2500.0) 125.0 (100.0, 900.0) 210.0 (20.0, 4500.0)
Intraoperative Transfusion Requireda 2 (5.6%) 4 (9.1%) 1 (4.8%) 7 (6.9%)
Presence of inflamed or Calcified Tissue/Vesselsa 10 (27.8%) 4 (9.1%) 1 (4.8%) 15 (14.9%)
Length of Stay (nights)
Mean (SD) 8.6 (5.7) 3.3 (2.4) 12.7 (6.1) 7.1 (5.9)
Median (Min, Max) 7.0 (2.0, 29.0) 3.0 (1.0, 11.0) 11.0 (5.0, 26.0) 5.0 (1.0, 29.0)
a Percentage calculated using the total procedures in each group as denominator.
Table 4
Hemostasis Grade 4 transections and hemostatic interventions used.
Grade 4 Vessels (n) Additional Hemostatic Product Used
Left uterine artery & vein (2) Suture
Left uterine artery (2) Suture
Right uterine artery (4) Suture
Right ovarian artery (1) Suture
Short gastric (2) Suture (1); Hemoclip (1)
Gastroepiploic (1) Suture
Table 5










AEs 55 43 24 122
SAEs 6 2 7 15
CD Score n (%)a
Grade I 38 (69.1%) 34 (79.1%) 5 (20.8%) 77 (63.1%)
Grade II 12 (21.8%) 9 (20.9%) 9 (37.5%) 30 (24.6%)
Grade IIIa 1 (1.8%) 0 (0.0%) 8 (33.3%) 9 (7.4%)
Grade IIIb 2 (3.6%) 0 (0.0%) 1 (4.2%) 3 (2.5%)
Grade IVa 2 (3.6%) 0 (0.0%) 1 (4.2%) 3 (2.5%)
Device-Related
AEs 2 2 0 4
SAEs 0 0 0 0
CD Score n (%)a
Grade I 2 (3.6%) 2 (4.7%) 0 4 (3.3%)
a Percentage of total AEs in each procedure group, including SAEs.
J. Schilder et al. / International Journal of Surgery Open 24 (2020) 57e63 61vessels included ileocolic, middle and right colic, none of which
exhibited any bleeding issues. Among 156 total vessel transections
in the gynecologic group, 89.7% were first pass hemostasis. The ABP
device was particularly useful in gynecologic cancer cases where
omentectomy was required, with each of the 17 omental vessel
transections rated as Grade 1 hemostasis. Gynecologic procedures
also included 68 and 66 transections of uterine and ovarian arteries,
respectively, which were the most common vessels transected in
this group. Obvious intraoperative bleeding during hysterectomyDownloaded for Anonymous User (n/a) at The University of Edinbu
For personal use only. No other uses without permission. Cmay commonly occur from loss of hemostatic control of the
vascular pedicles associated with these vessels [14]. In this study,
suture was utilized for intervention in all 9 instances of uterine or
ovarian artery (Grade 4) bleeding, which provided successful he-
mostasis in each case. The other three occurrences of Grade 4 he-
mostasis occurred in thoracic procedures, but overall this group
also exhibited first pass hemostasis in a majority (93.3%) of tran-
sections. Among secondary endpoint measures, surgeons' re-
sponses to questionnaires indicated ease of use of the test device in
terms of positioning and firing relative to previous advanced bi-
polar devices. Tissue sticking, which can inhibit delivery of energy
to targeted vessels and disrupt sealing, was minimal.
The type and frequency of AEs, including those reported as
serious, were consistent with the types of procedures performed in
the study. For the events that were considered device-related, 3 of
the 4 were identified as having an unlikely relationship to the study
device. Moreover, none of the device-related AEs were serious.
Classification of AEs according to the CD surgical complications
scale indicated that a majority of AEs across all three procedure
groups were CD Grades I or II. No AEs from the gynecologic group
were scored higher than CD Grade II, despite a high proportion of
extensive operations such as abdominal hysterectomy with
salpingo-oophorectomy and 9 occurrences of hemostasis Grade 4
transections. Importantly, each of the 4 device-related AEs recor-
ded in the study were CD Grade I. Thus, the test device was
determined to have an acceptable safety profile among the three
open procedure groups.
Median intraoperative blood loss for all subjects was 210 ml and
given the prevalence of complex open operations in this study, it
was not surprising that intraoperative transfusions of blood or
blood products were required in 7 (6.9%) procedures overall. Only
one AE was reported (anemia) in which transfusion was necessary
as the action taken, and this non-serious event was scored as
Clavien-Dindo Grade II. In addition, one subject from the colectomy
group who underwent a Hartmann's procedure, experienced
intraoperative blood loss of 4500 ml that did require transfusion
intraoperatively as well as postoperatively prior to discharge. This
4500 ml blood loss was a result of intra-operative issues that were
not related to the study device or the specific transection that thergh from ClinicalKey.com by Elsevier on May 04, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
J. Schilder et al. / International Journal of Surgery Open 24 (2020) 57e6362study device was used for. For gynecologic surgeries, median blood
loss was 300ml, and intraoperative transfusions were performed in
4 (9.1%) procedures. Estimated median intraoperative blood loss
during abdominal hysterectomy with or without salpingo-
oophorectomy has been reported as 200e480 ml, with trans-
fusion required in up to 9.3% of cases [15,16]. Thus, blood loss re-
sults from the gynecologic group are consistent with published
data. Similarly, median blood loss during open transthoracic
esophagectomy was reported from 325 to 568 ml [17,18], which is
higher than the median volume observed in the current study for
thoracic procedures (125 ml). Taken together, the findings in this
study are consistent with effective hemostasis performance by the
ABP device.
Strengths of the study include the prospective, multi-center
design and a substantial number and variety of vessels transected
among three procedure groups. The use of devices in different
procedures is considered important in order to replicate real-world
practice. In addition, all sites used consecutive screening and
enrollment as well as broad inclusion/exclusion criteria to provide a
representative patient sample. The primary limitation was the
single-arm design (i.e. no comparator device) for evaluating per-
formance of the ABP test device. Although the novel hemostasis
grading scale certainly provided detail with regard to occurrence
and extent of vessel bleeding, it should be further studied in order
to confirm reproducibility and overall usefulness in surgical
applications.5. Conclusion
To our knowledge, this study represents the first published large
clinical analysis of the ABP device. Considering the types and fre-
quencies of AEs, the overall safety profile, and the rate of first pass
hemostasis, the ENSEAL® X1 Large Jaw Tissue Sealer was consid-
ered effective for open colectomy, thoracic, and gynecologic sur-
gery applications.Ethical approval
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